Cytek BioSciences, Inc. (CTKB): Price and Financial Metrics
GET POWR RATINGS... FREE!
CTKB Stock Price Chart Interactive Chart >
CTKB Price/Volume Stats
Current price | $10.96 | 52-week high | $28.70 |
Prev. close | $10.73 | 52-week low | $7.38 |
Day low | $10.58 | Volume | 634,600 |
Day high | $11.19 | Avg. volume | 962,228 |
50-day MA | $9.82 | Dividend yield | N/A |
200-day MA | $15.36 | Market Cap | 1.47B |
Cytek BioSciences, Inc. (CTKB) Company Bio
Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Its customers include pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. Cytek Biosciences, Inc. was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. The company was incorporated in 2014 and is headquartered in Fremont, California.
Latest CTKB News From Around the Web
Below are the latest news stories about Cytek Biosciences Inc that investors may wish to consider to help them evaluate CTKB as an investment opportunity.
Cytek Biosciences Non-GAAP EPS of $0.09 misses by $0.02, revenue of $127.95M beats by $2.53MCytek Biosciences press release (CTKB): FY Non-GAAP EPS of $0.09 misses by $0.02.Revenue of $127.95M (+37.8% Y/Y) beats by $2.53M. |
Cytek Biosciences, Inc.''s (CTKB) CEO Wenbin Jiang on Q4 2021 Results - Earnings Call TranscriptNo summary available. |
Cytek Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results2021 Revenue Increased 38% Compared to Prior Year |
Boeing And 3 Other Stocks Bought By InsidersUS stocks closed mixed on Wednesday following the release of minutes from the recent Federal Reserve meeting. Investors, meanwhile, focused on some notable insider trades. When insiders purchase shares, it indicates their confidence in the company''s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga''s insider transactions platform. Cytek Biosciences The Trade: Cytek Biosciences, Inc. (NASDAQ: CTKB ) Director Rajeev Shah acquired a total of 498,629 shares at an average price of... |
Cytek to Participate in the 42nd Annual Cowen Health Care ConferenceFREMONT, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company will be participating virtually in the upcoming 42 nd Annual Cowen Health Care Conference. |
CTKB Price Returns
1-mo | 1.01% |
3-mo | 4.28% |
6-mo | -30.28% |
1-year | N/A |
3-year | N/A |
5-year | N/A |
YTD | -32.84% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
2018 | N/A |
2017 | N/A |
Loading social stream, please wait...